Samer Ezziddin retweeted
Ukraine is paying a high price in blood and terror. They are not the first and will not be the last if Russia isn’t defeated now. This is the lesson I wish the West would finally figure out. The price always goes up. There will be no better chance than now.
Samer Ezziddin retweeted
📣 Just released! Joint @EANM_NucMed @SNM_MI Lu-177 PSMA guidelines. Step forward in improving the standard of care for delivery of radioligand therapy. @ProfKHerrmann
link.springer.com/article/10…
Samer Ezziddin retweeted
Metastasis-directed therapy (MDT) in prostate cancer with SABR/SBRT and sLND:
- postpone need for ADT
- improved PFS
- one study with improved OS with SOC + SABR
@jeffkarnesMD @MayoUrology #AUA23
Terbium-161 may become an interesting alternative to Lutetium-177, here an example in PSMA-targeted Radioligand Therapy…. #Terbium #Tb161 #RLT #PSMA #prostatecancer
115
Samer Ezziddin retweeted
#ProPSMA 54 month follow-up #EAU23 "live" @declangmurphy
✓ PSMA PET/CT N1 prognostic for failure - HR 2.1
✗ CT/BS not prognostic
= PSMA PET/CT findings significant. More and more longer term data supporting it's use.
Presented by @veerukasi Funding @MovemberAUS @PCFA @pros_tic
Samer Ezziddin retweeted
Saw another patient this week misclassified as progression on DOTATATE PET/CT when the change was likely due to commencement of long-acting octreotide therapy. "Pseudoprogression" under-recognised phenomenon:
cancerimagingjournal.biomedc…
@globeseek @marklewismd @OncoThor
Radioliganden-Therapie: Wie eine neue Behandlung Prostatakrebs schrumpfen lässt welt.de/wissenschaft/plus244… via @welt
33
Samer Ezziddin retweeted
🤖🧠 #RobotischeNeurochirurgie: Präzise OPs ohne ermüdende oder zitternde Hände & Arme - Prof. Uwe Spetzger erklärt #Robotik im Spezialisten-#Podcast 🆕🆓🎧 primomedico-fachaerzte-talk.…
🏅 PRIMO MEDICO #Neurochirurgie @KlinikKarlsruhe 💡 primomedico.com/de/spezialis…
PSMA-Therapie für die Behandlung des metastasierenden Prostatakarzinoms ... youtu.be/u561628YL64 via @YouTube
Samer Ezziddin retweeted
Very excited to announce our latest Lu-PSMA trial @PeterMacCC: Ph I/II LuCAB trial (Lu-PSMA + cabazitaxel) for mCR #ProstateCancer. Target accrual 40 pts. Strong rationale for combining Lu-PSMA with cabazitaxel - radiosensitisation, Rx PSMA-neg disease, use 2 drugs that ⬆️ OS.
Samer Ezziddin retweeted
Nice illustration of (very) late PSMA PET imaging at +3 days with Zirconium-89: Digestive activity and late tracer retention in a local recurrence focus of prostate cancer after surgery. By Florian Rosar and Samer Ezziddin @Prof_Ezziddin #PSMA #theranostics #prostatecancer #PETCT
Samer Ezziddin retweeted
🆕🎧🆓Neuer #Podcast: PSMA #RadioligandenTherapie, realisierte Traumbehandlung bei #ProstataKrebs, mit Prof. Samer Ezziddin vom Universitätsklinikum des Saarlandes. Jetzt anhören! primomedico-fachaerzte-talk.…
👉PRIMO MEDICO #NuklearMediziner: primomedico.com/de/spezialis…
#ProstataKarzinom
Samer Ezziddin retweeted
#Nuklearmedizin: Mit einer Bestrahlung durch radioaktive Substanzen wie etwa Lutetium-177 können Prostatatumore sowie ihre Metastasen zumindest eine Zeitlang unter Kontrolle gebracht werden. @Saar_Uni @Prof_Ezziddin #Prostatakrebs #Strahlentherapie healthcare-in-europe.com/de/…
Samer Ezziddin retweeted
Plus accompanying editorial emphasizes this nicely @DrMLChua #prostatejc sciencedirect.com/science/ar… – at Melbourne, Victoria
Samer Ezziddin retweeted
#ASCOGU #GU21 #ProstateCancer #PSMA #theranostics
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial thelancet.com/journals/lance…
Samer Ezziddin retweeted
Just out in EJNMMI @SpringerOpen our systematic review of pre-treatment PET-CT derived parameters for outcome prediction in lymphoma - great work from Russell Frood @affrangi @DrChirag_Patel and others with important implications for future work
rdcu.be/cfyvr
Samer Ezziddin retweeted
A #cancer immunotherapy feature by @nytDeniseGrady nytimes.com/2016/07/31/healt…
nails both humanistic & science facets































